Moody���s: Pharma Asset Sales Might Hurt Credit Quality

but they are more stable, with ���lower R&D risk, less exposure to patent risk, and reduced litigation threats.��� (Merck has decided to hang on to its consumer and animal businesses after all, calling them ���great assets.���) Finally, if a company...